abnormalities. In a multivariable logistic regression model, older age (per 5-year increase: OR = 1.31, 95 % CI = 1.08, 1.60) was associated with the development of at least one new ECG abnormality, while serum HDL cholesterol (per 10-unit increase: OR = 0.98, 95 % CI = 0.96, 1.00) was protective against developing new ECG abnormalities. Conclusions The development of new ECG abnormalities is common in type 1 diabetes. Older age and HDL cholesterol are independent risk factors for developing new ECG abnormalities. Further research is needed to determine whether routine ECG screening is indicated in people with type 1 diabetes to identify those with underlying subclinical coronary heart disease.
Introduction
Type 1 diabetes is a well-known risk factor for adverse cardiovascular outcomes, including mortality [1] [2] [3] . This increased risk of cardiovascular events largely is related to the increased prevalence of silent myocardial ischemia and infarction due to underlying coronary artery disease and cardiac autonomic neuropathy [4] [5] [6] . Symptoms of ischemia occur late, and it is thought to be preceded by subclinical changes in left ventricular function that result in electrocardiogram (ECG) abnormalities.
Persons with long-standing type 1 diabetes have an increased prevalence of abnormalities on the standard 12-lead ECG [7] . However, less is known about the incidence and determinants of developing such abnormalities in persons with type 1 diabetes. The purpose of this analysis was to examine predictors of new ECG abnormalities in type 1 diabetes in the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR).
Methods

Study population
The WESDR cohort has been previously described [2] . Briefly, this cohort included 1210 persons with type 1 diabetes who received primary care in an 11-county area of southern Wisconsin between July 1, 1979 and June 30, 1980. Participants were followed for 32 years and have completed a total of 7 study visits [8] . Study examinations were performed in mobile examination centers and clinics near each participant's place of residence, or in the participant's residence. During each visit, trained staff conducted physical examinations and collected information regarding medical history, medication use, and blood and urine samples. Written informed consent was obtained before each examination and all examinations followed protocols approved by the Institutional Review Board at the University of Wisconsin.
Resting 12-lead ECGs were not obtained until study visit 5 (2000-2001) . This analysis included participants with complete ECG data from that visit and also from study visit 7 (2012-2014) to examine predictors of ECG abnormalities between visits.
Electrocardiography
WESDR participants had 12-lead resting ECGs recorded during visits 5 and 7. Tracings were read at the Epidemiological Cardiology Research Center of the Wake Forest School of Medicine (Winston-Salem, North Carolina). ECG abnormalities from each visit were classified as major and minor using Minnesota Code Classification [9] . Major ECG abnormalities included major ventricular conduction defects (complete left or right bundle branch block, major ventricular conduction delay with QRS ≥120 ms), definite myocardial infarction (defined as the presence of major Q wave abnormalities), possible myocardial infarction (defined as the presence of minor Q/QS wave plus major ST/T abnormalities), isolated major ST/T wave abnormalities, left ventricular hypertrophy with strain pattern, advanced atrioventricular conduction abnormalities (complete or second-degree AV block), pacemaker, atrial fibrillation/flutter, and others. Minor ECG abnormalities included minor isolated Q/QS wave abnormalities, minor isolated ST/T abnormalities, high R waves/increased QRS voltage denoting left or right ventricular hypertrophy without strain pattern, non-ischemic ST segment elevation, incomplete (left or right) bundle branch block, short PR interval, left axis deviation, right axis deviation, atrial and ventricular premature beats, and others. In this study, we focused on the development of major ECG abnormalities (defined as presence of at least one major ECG abnormality) and any ECG abnormalities (at least one major or minor ECG abnormality) during study visit 7. The development of a new abnormality was able to exist in the presence of a different abnormality detected at baseline.
Covariates
Age, sex, and smoking status (current, past, or never) were self-reported. Duration of diabetes was defined as the time between each participant's age at diagnosis until the age at WESDR visit 5. Fasting blood samples were obtained and assayed for glycated hemoglobin A1c, high-density lipoprotein (HDL) cholesterol, and total cholesterol. Body mass index was computed as the weight in kilograms divided by the square of the height in meters. The current use of antihypertensive medications and lipid-lowering therapies was self-reported. After the participant rested for 5 min in a seated position, blood pressure was measured using a sphygmomanometer. Two values were obtained following a standardized protocol and averaged. Hypertension was defined as systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or by the use of antihypertensive medications. Using serum creatinine measurements from the baseline study visit, estimated glomerular filtration rate (eGFR) was estimated using the CKD-EPI equation [10] . Urine samples were used to compute albumin-to-creatinine ratio (ACR) for study participants, and protein dipstick tests were used to determine whether gross proteinuria was present. Chronic kidney disease (CKD) was defined as eGFR values <60 mL/min/1.73 m 2 or ACR ≥30 mg/g, or if urine dipstick tests were positive for protein.
Statistics
Baseline characteristics were stratified by the presence of ECG abnormalities. Categorical variables were reported as frequency and percentage, while continuous variables were reported as mean ± standard deviation. Statistical significance of baseline categorical variables was tested using the Chi-square method and the student's t test for continuous variables. To determine whether predetermined baseline predictors (age, sex, duration of diabetes, current smoking, body mass index ≥30 kg/m 2 , hypertension, history of use of antihypertensive medications and lipid-lowering therapies, glycated hemoglobin A1c ≥7 % (53 mmol/mol), serum HDL cholesterol, total cholesterol, or CKD) were associated with the development of new ECG abnormalities, logistic regression was used to compute odds ratios (OR) and 95 % confidence intervals (CI) for the association between each predictor and each outcome. Multivariable models were as follows: Model 1 adjusted for demographics (age and sex); Model 2 adjusted for Model 1 covariates plus factors that possibly influenced ECG abnormality development (duration of diabetes, current smoking, body mass index, hypertension, glycated hemoglobin A1c, serum HDL cholesterol, total cholesterol, lipidlowering medication, and CKD). Statistical significance was defined as P values < 0.05. SAS ® version 9.3 (SAS Institute, Cary, NC) was used to conduct all analyses.
Results
A total of 266 (mean age = 44 years ± 9.0; 50 % female) participants with complete ECG data from both visits were included in the final analysis. At baseline, 94 (35 %) participants had at least one ECG abnormality and 13 (4.9 %) had a major ECG abnormality. The most common minor ECG abnormalities were incomplete left bundle branch block (n = 26, 9.8 %) and minor Q waves (n = 17, 6.4 %). The most common major ECG abnormalities at baseline were isolated major ST/T abnormalities (n = 5, 1.9 %) and ECG evidence of old myocardial infarction (major Q waves; n = 4, 1.5 %). Baseline characteristics stratified by major and any abnormalities are shown in Table 1 .
Between study visits, a total of 117 (44 %) participants developed at least one new ECG abnormality (major or minor) and 35 (13 %) developed at least one new major ECG abnormality. The most common new minor ECG abnormalities were minor isolated ST/T abnormalities (n = 30, 12 %) and minor Q waves (n = 27, 11 %), while the most common new major ECG abnormalities were isolated major ST/T abnormalities (n = 20, 7.7 %), complete right bundle branch block (n = 7, 2.7 %), and minor Q, QS waves with ST/T abnormality (n = 7, 2.7 %). Table 2 shows the distribution of new ECG abnormalities detected during study visit 7 stratified by age, sex, duration of diabetes, smoking, body mass index, hypertension, glycated hemoglobin A1c, and CKD. The distribution of each ECG abnormality detected at follow-up is shown in Supplemental Table 1 . In a multivariable model, older age was associated with the development of at least one new ECG abnormality, while current smoking and HDL cholesterol were less likely to develop new ECG abnormalities (Table 3) . None of the predetermined predictors examined were associated with the development of major ECG abnormalities.
Discussion
In this analysis from WESDR, ECG abnormalities were highly prevalent in this population of type 1 diabetes and the development of new ECG abnormalities was very common on repeat ECG measurement. Older age and low serum HDL cholesterol were identified as independent risk factors for developing new ECG abnormalities. Although current smoking was shown to be protective against developing new ECG abnormalities, this likely is related to a survival effect, as other cohort participants who smoked died earlier in the study period.
ECG abnormalities have been shown to be highly prevalent in WESDR [7] . Our study builds on prior findings to show that this population is at risk for developing new ECG abnormalities that likely reflect underlying subclinical events related to silent ischemia. This is supported by studies which have shown that persons with diabetes are known to have cardiac autonomic neuropathy in which silent ischemia occurs without the presence of cardinal cardiac symptoms [11, 12] .
The development of new ECG abnormalities was more common with older age and low serum HDL cholesterol. Aggressive lipid management is recommended in diabetes [13] , and reductions in the progression of ECG abnormalities potentially will occur with intensive lipid management. However, further research is needed to explore this hypothesis in people with type 1 diabetes. Nonetheless, we have identified two risk factors associated with the development of ECG abnormalities in type 1 diabetes that should alert practitioners to the possibility of underlying silent ischemia.
The development of new ECG abnormalities was not found to be different between men and women. Similar findings have been reported from WESDR regarding the development of cardiovascular disease, including myocardial infarction [2] . Presumably, our findings are explained by the loss of premenopausal cardioprotection observed in women with type 1 diabetes [14] . Therefore, it would be expected that no differences in ECG abnormalities would be detected by sex.
Data from the Diabetes UK cohort which consisted of nearly 23,000 insulin-treated people with diabetes have shown that an increased risk of mortality from ischemic heart disease exists in this population [1] . A prior report from this cohort has demonstrated that an increased risk for cardiovascular events and cardiovascular mortality exists in persons with long-standing type 1 diabetes [2] . Additionally, data from the Canterbury Diabetes registry have demonstrated cardiovascular disease accounts for the single greatest cause of excess mortality in type 1 diabetes [3] . In aggregate, these data suggest that persons with type 1 diabetes merit close surveillance and risk factor modification strategies to reduce the risk of adverse cardiovascular events. Due to its low cost and widespread availability, the 12-lead ECG possibly is a cost-effective tool to identify subclinical coronary artery disease (e.g., ECG abnormalities) in type 1 diabetes and alert providers to the presence of likely myocardial injury in persons without clinical symptoms. Therefore, further studies are needed to determine whether routine ECG screening in type 1 diabetes with targeted interventions to reduce the burden of ischemic heart disease is warranted. The current study should be interpreted in the context of several limitations. We examined the association between several potential predictors of developing new ECG abnormalities in a population with long-standing type 1 diabetes, and differences possibly exist in persons with shorter disease duration. This analysis required complete ECG data from 2 study visits approximately 10 years apart. New abnormalities that coincided with death were undetected, and this limits the generalizability of our results to persons without fatal coronary heart disease events. Additionally, our study possibly was underpowered to detect other significant predictors due to the limited number of participants with complete ECG data. Similarly, the current study was underpowered to detect differences for each individual ECG abnormality and a global classification (e.g., any new major abnormality) system was used [15, 16] . Several baseline covariates were self-reported and subjected our analysis to recall and misclassification biases. Furthermore, residual confounding remains a possibility similar to other observational studies.
In conclusion, we have shown that the development of new ECG abnormalities is common in type 1 diabetes. Additionally, older age and HDL cholesterol were identified as independent risk factors for developing new ECG abnormalities. Further research is needed to determine whether routine ECG screening in persons with type 1 diabetes is able to identify those with underlying silent ischemia who merit intensive cardiovascular risk assessment to reduce the burden of adverse cardiovascular events in this population.
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